Focus articles on the therapeutic options for acute and advanced heart failure are available here, containing new data, new studies, new opinions and new trends from Professor Gerhard Pölzl, Chief of the Heart Failure and Heart Transplant Program at the Medical University Innsbruck. His research is focused on clinical studies in advanced and chronic heart failure and on translational studies in cardiomyopathies.
He was Principal Investigator of the LevoRep clinical trial that tested the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure. He is now PI of the clinical trial LEODOR, on repetitive use of levosimendan in advanced heart failure.
See Professor Gerhard Pölzl preview the upcoming Heart Failure Congress 2019, and see what is included in the program.
Explore the April 2019 blog from Professor Gerhard Pölz focuses on some of the recent literature he has read.
See as Professor Pölzl gives an update on the progress of the LeoDOR study which is the first major trial of intermittent levosimendan.
Professor Pölzl discusses levosimendan and the REFALS 3 trial, which will evaluate the impact of levosimendan on respiratory function in patients with acute lateral sclerosis (ALS).
Professor Pölzl highlights a Supplement added at the end of 2018 to the European Heart Journal.
At ESC-HF 2018 experts discussed how to use levosimendan safely and effectively in acute and advanced heart failure, including in the context of renal dysfunction.
Discussion on levosimendan therapy in the LION-HEART RCT and heart failure as a 'final-stage' condition.
Thoughts from the expert meeting organised by the Heart Failure Clinic, Attikon University Hospital, 2018.
Professor Gerhard Pölzl discusses the 2018 European Society of Cardiology annual meeting, which included the outcome of the VERDICT trial.
The HFA-ESC has issued a fresh position paper [Crespo-Leiro MG et al. Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236]. Here’s our first take on some highlights.
If we had a way to reduce the risk of life-threatening complications after cardiac surgery would we use it? Of course we would. It is for reason that this blog post highlights the recent work of Dr. Qiang and colleagues. See the details here.
Professor Cynthia M Dougherty and colleagues outline an array of options for the treatment of advanced heart failure (HF) that create – quite reasonably – the impression that we are in a golden age of therapeutic possibilities for this difficult condition.
There have been some recent achievements in the LEODOR trial including a new website to facilitate administration and communication and submission of a formal study protocol synopsis to the European Journal of Heart Failure.
Professor Gerhard Pölzl reports primary results from the LION-HEART study in the management of advanced heart failure where among secondary endpoints, patients treated with levosimendan experienced a reduction in the rate of HF-related hospitalisation compared with placebo.
Professor Gerhard Pölzl highlights Hospitalisation for the management of acute decompensation being a critical moment in the trajectory of heart failure (HF) and one that has gloomy prognostic implications for many patients.
Professor Gerhard Pölzl discusses the interplay between the acutely compromised heart and the kidneys and how the optimal treatment for individual cases is complex.
Professor Gerhard Pölzl highlights advanced heart failure and treatment options available for those patients that are critically vulnerable.
Professor Gerhard Pölzl discusses the European Society of Cardiology annual meeting 2017, where several sessions were held on the use of levosimendan in heart failure.
Professor Gerhard Pölzl highlights the LION-Heart and LAICA clinical trials.
Professor Gerhard Pölzl discusses heart failure as the leading cause of adult hospitalisation in the industrialised world and what can be done to reduce this burden.
Professor Gerhard Pölzl highlights the significance of the FIGHT, PERSIST and LEVOREP trials which investigate levosimendan as a treatment for heart failure.
Professor Gerhard Pölzl discusses the Heart Failure Association of the European Society of Cardiology annual meeting, where several sessions were held on the use of levosimendan in heart failure.